The risk of adverse events, including serious adverse events and serious infectious events, was greater in patients treated with tofacitinib than in those who received placebo, at month 3. Patients receiving tofacitinib must be monitored by their physician for such events. Notable adverse events included cytopenia, which may be attributable to the inhibition of JAK2; infections ; and gastrointestinal side effects. There were two instances of pulmonary tuberculosis . Changes in laboratory values which were observed with both doses of tofacitinib, in comparison with placebo, included small boosts in serum creatinine boosts and levels in imply levels of LDL and HDL cholesterol. The consequences of tofacitinib on lipid profiles aren’t completely understood still.This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an unbiased news service editorially, is a scheduled program of the Kaiser Family members Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente.. Additional data in lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting Sucampo Pharma European countries, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc. The info presented reflect extra analyses of currently disclosed phase 2 and phase 3 scientific trials of lubiprostone in patients with persistent idiopathic constipation and in patients identified as having or reporting irritable bowel syndrome with constipation .